BOSTON — Alloy Therapeutics Inc., a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, has announced the acquisition of Spannerwerks LLC, a Seattle-based professional services firm that guides biopharmaceutical companies in the development and launch of new products.
Under the terms of the agreement, Spannerwerks will operate as a wholly owned subsidiary of Alloy Therapeutics and continue to serve its clients under the Spannerwerks name. CEO Dara Lockert will join Alloy full-time and continue to lead the team as part of the company’s leadership group.
The acquisition marks a major step in Alloy’s expansion beyond discovery and into drug development, broadening its ability to help partners progress efficiently toward key value inflection points.
“Alloy has seen how critical it is for biotech innovators to access the right expertise at the right time,” said Errik Anderson, CEO and Founder of Alloy Therapeutics. “By combining Alloy’s discovery platforms with Spannerwerks’ preclinical and clinical development capabilities, we’re giving our partners more flexibility, speed, and expert support to move their programs from idea to patients.”
Founded in 2015, Spannerwerks has earned a reputation as a trusted partner for pharmaceutical and biotech companies, helping them advance programs toward the clinic through a cost-effective, operationally focused approach to drug development. The firm specializes in development candidate selection through early clinical stages, offering cross-functional expertise across program management, toxicology, chemistry manufacturing and controls (CMC), regulatory affairs, quality, and clinical operations. Spannerwerks continues to support a wide range of therapeutic modalities including small molecules, antibody-drug conjugates (ADCs), cell therapies, gene therapies, and monoclonal and bispecific antibodies.
“Joining the Alloy ecosystem allows us to amplify what we do best: helping emerging biotechs navigate the complex and ever evolving path to the clinic,” said Dara Lockert, CEO of Spannerwerks. “We’re excited to bring our team and expertise to a broader set of partners where we can deliver even more value to innovators who are working to bring transformative new medicines to patients.”
The acquisition strengthens Alloy’s commitment to supporting partners across the entire R&D lifecycle—from discovery through development—and enhances its ability to de-risk the journey to the clinic without inflating costs. With this expansion into the Pacific Northwest, Alloy extends its global presence and connects its collaborative ecosystem to a world-class hub of drug development expertise. By uniting complementary teams with shared values and a focus on scientific excellence, Alloy aims to accelerate the delivery of impactful new medicines to patients worldwide.
